BI Asset Management Fondsmaeglerselskab A S Sells 12,283 Shares of IQVIA Holdings Inc. $IQV

BI Asset Management Fondsmaeglerselskab A S trimmed its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 55.0% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 10,036 shares of the medical research company’s stock after selling 12,283 shares during the quarter. BI Asset Management Fondsmaeglerselskab A S’s holdings in IQVIA were worth $1,712,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in IQV. Ameliora Wealth Management Ltd. bought a new stake in shares of IQVIA in the 4th quarter valued at $25,000. International Assets Investment Management LLC bought a new position in IQVIA during the fourth quarter worth about $27,000. Gilpin Wealth Management LLC acquired a new position in IQVIA in the fourth quarter valued at about $27,000. CrossGen Wealth LLC bought a new stake in shares of IQVIA in the fourth quarter worth about $28,000. Finally, Measured Wealth Private Client Group LLC bought a new stake in IQVIA during the 3rd quarter worth approximately $30,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Stock Up 8.5%

IQVIA stock opened at $185.76 on Thursday. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.20. IQVIA Holdings Inc. has a 1-year low of $154.50 and a 1-year high of $247.04. The company has a fifty day simple moving average of $173.95 and a 200 day simple moving average of $190.34. The company has a market cap of $31.00 billion, a P/E ratio of 23.02, a price-to-earnings-growth ratio of 1.47 and a beta of 1.21.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, topping analysts’ consensus estimates of $2.83 by $0.07. The company had revenue of $4.15 billion during the quarter, compared to the consensus estimate of $4.10 billion. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The company’s quarterly revenue was up 8.4% on a year-over-year basis. During the same period in the prior year, the business posted $2.70 EPS. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Research analysts anticipate that IQVIA Holdings Inc. will post 11.6 earnings per share for the current fiscal year.

IQVIA declared that its Board of Directors has authorized a share buyback program on Thursday, May 7th that permits the company to buyback $2.00 billion in outstanding shares. This buyback authorization permits the medical research company to repurchase up to 6.8% of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s management believes its shares are undervalued.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. Weiss Ratings lowered shares of IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday, May 4th. Barclays raised shares of IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 price objective on the stock in a research report on Friday, March 6th. Wall Street Zen upgraded IQVIA from a “hold” rating to a “buy” rating in a report on Sunday, June 14th. Morgan Stanley reissued an “equal weight” rating and issued a $200.00 price target (down from $225.00) on shares of IQVIA in a research note on Wednesday, June 17th. Finally, Royal Bank Of Canada initiated coverage on IQVIA in a report on Tuesday, March 3rd. They set an “outperform” rating and a $221.00 price objective for the company. Two investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, IQVIA currently has a consensus rating of “Moderate Buy” and a consensus price target of $222.56.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.